Abstract
. The genetic predisposition accounts for only 5-10% and is associated with early onset [2, 3] .
Given the aging population in Western countries, the grave suffering of the many individuals concerned and their families, and the increasing economic cost of AD in terms of both healthcare expenses and lost wages it makes it important to understand the disease mechanisms and propose effective treatment strategies. [6] . Complement proteins are reported to be integral components of amyloid plaques and cerebral vascular amyloid in AD. They are found at the earliest stages of amyloid deposition and their activation coincides with the progressive clinical manifestation of AD [7, 8] .
The clinical manifestation of AD is considered to be correlated with the degree of neuronal loss in the brain and more specifically in hippocampal and neocortical areas. While AD can be identified based on clinical symptoms and by excluding other conditions with similar phenomenology and psychopathology, a definite diagnosis is only possible post-mortem by histological analysis of the patient's brain. Extracellular senile (amyloid) plaques and intracellular neurofibrillary tangles (NFTs) are considered to be hallmarks of the disease [4]. Senile plaques contain extracellular deposits of amyloid-␤ protein (A␤), ␣-synuclein, ubiquitin and apolipoprotein E. NFTs are intracellular and extracellular aggregates of hyperphosphorylated protein and apolipoprotein E [5]. Evidence that A␤ alone is not sufficient for initiating the pathophysiological cascade of AD came from experiments with transgenic mice, which suggested that sustained brain inflammation might be another essential factor in AD pathogenesis. Different inflammatory markers such as activated microglia and astrocytes, elevated levels of various cytokines and complement activation products are found in AD brains
Here we review the interrelationship between different risk factors for AD aetiology with particular emphasis on their role for neuronal death as well as different strategies for neuroprotection as a potentially promising therapeutic strategy. [9] [10] [11] [12] [13] [14] . However, this hypothesis became even more attractive when it was demonstrated that the mediators and products of inflammatory reaction, such as cytokines [15, 16] , complement proteins (reviewed in [17] ), free radicals [18, 19] , adhesion molecules [20, 21] and prostaglandins (reviewed in [22] ), were neurotoxic in experiments with neural models. These products of inflammatory reactions may represent extracellular signals which initiate and promote neuronal degeneration in AD. For instance, long-time administration of NSAIDs to arthritic patients can reduce the risk of developing AD [7, 11] . Potent inflammatory molecules, such as cytokines, chemokines and complement factors, are present in both cerebrospinal fluid (CSF) and plaques from patients with AD [7] . Aggregated [26, 27] , ubiquitin [28, 29] and proteasome [30] [31] [32] . The [68] and complement components [69, 70] [76] (Fig. 2) [80] .
Origin of the disease and mechanisms for neuronal death in AD

Inflammatory reaction
This hypothesis is based on observations that non-steroidal antiinflammatory drugs (NSAIDs) can reduce neurotoxins in patients suffering from AD. In epidemiological and clinical studies, it was initially noted that patients on high doses of anti-inflammatory drugs exhibit a reduced incidence of AD and reduced the AD symptoms
peptides, such as A␤ are shown to induce the production of pro-inflammatory cytokines like interleukin (IL)-1␤, tumour necrosis factor (TNF)-␣ and chemokines (MIP-1␣, MIP-1␤, MCP-1) by microglial cells [23-25]. These inflammatory molecules were found to be toxic in neuronal models of AD and were implicated in extracellular signalling which initiated and promoted neuronal degeneration in AD. Several intracellular signals are candidates for mediating actions of inflammatory factors inside the cells such as A␤
A␤-induced neurotoxicity
Although it is still disputable if complement system is a primary cause of neuronal degeneration or a secondary event in AD [81] [82, 83] .
Oxidative and nitrosylative damage
This hypothesis emphasizes the role of reactive oxygen and nitrogen species (ROS or RNS) in initiation and promotion of neurodegeneration in the brains of AD patients [18, 19]. Some of these radicals originate from normal brain function processes: it is known that the brain utilizes about 25% of respired oxygen and that about 2% of the oxygen consumed converts into ROS. Other free radicals are released during inflammatory reactions and by A␤. This hypothesis for the AD aetiology is supported by the observation in some clinical trials that high doses of antioxidants might be beneficial to AD patients
Increased oxidative stress may enhance intracellular accumulation of A␤ in neurons [84] . In addition, studies show that membranes containing oxidatively damaged phospholipids accumulated A␤ faster than membranes containing only normal saturated phospholipids [85] . Based on this finding, it was proposed that one or some of the mechanisms of action in A␤ neurotoxicity might be free-radical mediated [86] . Further studies on protection of cultured neuronal cells against A␤-induced toxicity by vitamin E supported this hypothesis [87] . Additional evidence of increased oxidative stress in AD include: AD patients have lower levels of vitamins A, E and ␤-carotene in their serum compared to control patients [88] ; increased consumption of oxygen is found in AD patients [89] ; activation of calcium-dependent neural proteinase (calpain), triggering formation of free radicals, was found in AD autopsy brain samples [90] 
Proteasome inhibitor-induced neurotoxicity
Numerous studies now clearly demonstrate that inhibition of the proteasome is sufficient to induce cell death in both neuronal and [104, 105] .
However, proteasome inhibition does not induce neuronal death in all neuron populations or experimental setups [106, 107] . [108, 109] [119] , APP processing [120] , and possible involvement of APP in the intraneuronal traffic of the virus [121] . Herpes infection was shown to increase the production of A␤ in mouse brains [122] . Numerous [123] [124] [125] [126] [127] and/or certain types of viral infections [128] [129] [130] [131] [135] . A cytokine-dependent enhancement of A␤ production from APPexpressing astrocytes and cortical neurons in transgenic mice was also demonstrated [136] . Furthermore, HSV-1 protein ICP27 has been shown to inhibit host cell splicing [137] [138] [139] by altering phosphorylation of SC35 and other proteins [140] , which we showed to yield in accumulation of A␤ [135] . Cholesterol and other 'raft' lipid components, such as sphingomyelin and galactosylceramide, induce aggregation of the secreted A␤ peptide [141, 142] [151] . Clinical studies demonstrate that the drug has rather symptomatic benefits for patients than a disease modifying effect [152, 153] .
It seems that proteasome inhibitor-induced toxicity is cell-type specific. It was demonstrated that proteasome inhibition could have very different effects on cell death based on the differential role of NF-B -a downstream proteasome target which can have pro-apoptotic or anti-apoptotic effects depending on cell type
. In transferring the knowledge obtained from in vitro studies to studies in the mature CNS, it is important to consider the fact that the majority of in vitro studies are conducted in cultures established from embryonic tissues or early postnatal brain. One thus must take into account the possibility that embryonic tissue may have a different dependence on proteasome activity than established neurons within the developed and mature, or, as in the case of AD patients, aged CNS. Only recently, the importance of the proteasome in the physiology and pathology of the CNS has begun to emerge. It is likely that studies on this intriguing enzyme will yield further important information on how oxidative stress occurs in the CNS and how CNS protein turnover is regulated. Ultimately, this may lead to the design of useful new therapeutic strategies aimed at eliminating oxidative stress toxicity in the CNS, thereby contributing to the prevention and/or amelioration of clinical AD symptoms.
Cholesterol-induced neurotoxicity
increase the risk of AD. These two risk factors, however, are accompanied by a chronic inflammatory reaction leading to the release of a number of cytokines, including interferon (IFN)-␥ and TNF-␣. An inhibitory effect of IFN-␥ on the translational machinery has been well-documented [132-134], leading to lower expression of proteins, including SC35 and hnRNPA1, whose downmodulation results in increased secretion of A␤ by cultured neurons
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␤-and ␥-secretase inhibitors ␤ and ␥ secretases are the two enzymes critically responsible for the formation of amyloid plaques (Fig. 1) [154] . Clinical data support this approach since activity of ␤-secretase increases with age [155] . [156] . The crystal structure of BACE1 shows that the active site is comprised a long cleft for substrate recognition [157] . [162, 163] [171, 172] dedicated specifically to this issue. [82] . Other clinical trials also failed to show beneficial effects of vitamin E administration to AD patients [173] [174] [175] . These results together with recent observations that high doses of vitamin E (Ͼ400 IU/day) may increase mortality [176] suggest that vitamin E should not be given as an additive to other therapeutic approaches for AD treatment. Clinical results for selegeline treatment have been rather controversial suggesting either only a small benefit or no significant improvement in the cognition of AD patients [177] .
Development of ␤-secretase inhibitors (BSI), however, has proven to be challenging and to date none has been tested extensively in human beings
The structural features of BACE1 are used for design of BSI. The first generation of BSI were designed as transition-state analogues for the aspartyle protease (e.g. OM99-2, KMI-429). The majority of commercially available potent BSI are peptide-based compounds containing a transition-state moiety (e.g. hydroxyethylene, statin, etc.). Promising recent data suggest that KMI-429, has great potential as it significantly reduced production and accumulation of senile plaques in vivo in brains of wild-type and transgenic mice [158]. A new generation of BSI was designed recently [159], containing hydroxyethylamine isostere and isophthalamide moiety (GRL-8234). This compound efficiently inhibits BACE1 activity not only in vitro but also in vivo. Another recently generated BSI containing a 2,6-pyridinedicarboxylyc, chelidamic or chelidonic residue at the P2 position together with hydroxymethylcarbonyl isostere (KNI-1027) was also shown to inhibit efficiently BACE1 [160]. Considering the usage of BSI as drugs, making less peptidic compounds is mandatory to obtain sufficient oral absorption and penetration through the blood-brain barrier. These two issues have hampered progress in development of BSI for AD therapeutics, however, recently was generated the first orally bioactive non-peptidic BSI, GSK188909, able to reduce brain A␤ levels in APP transgenic mice [161]. Although ␥-secretase has in many ways been an attractive target for AD therapeutics, interference with Notch processing and signalling may lead to toxicities that preclude clinical use of inhibitors of this protease. Knockout of Notch1 or PS1 is embryonic-lethal in mice
Drugs which potentially prevent and modify AD symptoms Vitamins and antioxidants Growing evidence supporting the oxidative stress hypothesis has led to the concept of using antioxidants such as vitamin E (␣-tocopherol) as a potential treatment approach in AD. However, vitamin E in combination with selegiline, a drug used for the treatment of early-stage Parkinson's disease, depression and senile dementia, showed no real benefits for the patients
The extract of the plant Ginkgo biloba was suggested to enhance cognition. In addition to putative antioxidant properties, the extract has been reported to reduce the aggregation of the A␤ peptide. However, in a randomized trial Ginkgo biloba did not significantly enhance memory in healthy elderly adults [178] .
Non-steroidal anti-inflammatory drugs
Retrospective observational studies have shown that the use of NSAIDs may have protective properties regarding the development of AD [10, [179] [180] [181] [182] . In epidemiological studies, the use of NSAIDs was associated with lower risk of developing AD and the benefits seem to be greater with long-term use [179] . However, NSAIDs only seem to offer protection if used before disease onset, treatment after the development of AD symptoms results in little or no benefit to the patients [183] [184] [185] [186] [187] . Therefore, currently NSAIDs are not used in the treatment of AD.
Oestrogen replacement therapy
Women have two-to three-fold higher age-specific prevalence rates of AD [188] . [188, 189] . An anti-inflammatory effect of the Premarin has also been demonstrated.
Women are oestrogen deficient after menopause, whereas men rather maintain hormone levels as testosterone undergoes aromatization to estradiol. Oestrogen is considered to have a number of beneficial features such as antioxidant and anti-inflammatory properties, interactions with neurotransmitters such as acetylcholine, and an ability to alter apolipoprotein which could lower the risk of developing AD. In vivo studies with low doses of conjugated oestrogen (Premarin) in a rat model showed that this treatment can prevent vascular deposition of A␤, thus protecting the endothelial cell from toxic effects of the plaques
Inhibitors of complement-mediated degeneration
Recently we reviewed in detail the important dual role of the complement system and its regulators in brain inflammation and neuronal damage in AD [17]. This dual role should be carefully considered when choosing therapeutic targets for AD treatment. Until now, complement proteins and CRegs have been largely overlooked as targets for developing AD drugs, but accumulated data suggest that appropriate modulation of expression and/or activity of proteins controlling the complement cascade could be of great clinical benefit for AD patients.
Cobra venom factor (CVF)
The earliest indication that inhibition of complement might be of therapeutic benefit came from analyses of the effects of decomplementation with CVF [190] [191] [192] [193] [194] . CVF binds mammalian fB in plasma resulting in cleavage of fB by fD and production of C3 convertase [195] 
Heparin and other polyionic agents
Heparin, a polyanionic glycosaminoglycan, has long been recognized as an in vitro inhibitor of complement [196] . Heparin affects complement activation at multiple levels, by binding and inactivating C1, blocking generation of the C3 convertases and interfering with the assembly of MAC [197] [198] [199] [200] . Very few studies have addressed the potential use of heparin as a complement inhibitor in vivo. N-acetylated heparin with much reduced anticoagulant activity can inhibit CVF-induced complement activation in guinea pigs [201] . Further in vitro work on human samples demonstrated that heparins were much more efficient inhibitors in human than in guinea pig serum [202] . Interestingly, it was recently demonstrated that this drug can interfere with the metabolism of amyloid plaques and reduces the accumulation of A␤ [203] . Long-term treatment with enoxaparin, a low molecular weight heparin, in human APP751 transgenic mice can significantly reduce the deposition of amyloid plaques and A␤ aggregation [203] 
. Chronic treatment with enoxaparin is well tolerated and does not increase side effects such as haemorrhage in the brain. Although the exact mechanism is not yet clear, a reduced ability of A␤ to activate complement system and its classical pathway may play a role.
Numerous related and unrelated polyanionic molecules, including dextran sulphate, polyvinyl sulphate, polylysine and suramin, inhibit complement activation in vitro (reviewed in [204] ). However, their applicability in vivo and particularly for treatment of AD has not been investigated. [205, 206] . Rosmarinic acid, extracted from the common shrub Rosemary, covalently binds activated C3b and prevents formation of the convertase [207, 208] . An extract of the Chinese medicinal herb, Ephedra, inhibits complement at multiple levels including the terminal pathway [209] . Among the synthetic complement inhibitors, the protease inhibitor FUT-175 is one of the best investigated. It inhibits C1r, C1s, fD and the C3/C5 convertases [210, 211] . FUT-175 is effective in numerous animal models of complement-mediated disease [212, 213] 
Other small molecule inhibitors Many synthetic and natural molecules have been shown to inhibit complement activation in vitro. A few natural inhibitors have shown efficient complement inhibition both in vitro and in animal models. The molecule termed K-76COOH, isolated from cultures of the fungus Stachybotrys complementi, inhibits complement at the C5 stage
Recombinant protein inhibitors
In addition to the approaches described above, a plethora of soluble therapeutics has been developed which specifically inhibit the complement cascade [215] . Early agents were based on the naturally occurring membrane-associated CRegs, such as CD49, CD59 and Complement Receptor 1(CR1; CD35) . Removal of membraneanchoring domains using recombinant technology generated soluble molecules with the same regulatory functions as the 'parent' inhibitor which could be administered locally or systemically to inhibit complement. The best known of these is a soluble form of CR1 (sCR1), an agent developed nearly 30 years ago and used in the clinic, with limited success, for complement inhibition in myocardial infarction (MI) and cardiopulmonary bypass (CPB) [216] [217] [218] . These 'first-generation' agents have been engineered and modified over the years to improve characteristics such as half-life (by introducing antibody Fc domains) [219] , membrane localisation (by using lipid 'tails') [220] and specific targeting of complement activation sites (by using fusion proteins comprising a domain that binds C3 activation fragments, thus localising to the site of C attack) [221] . Some success has also been obtained using small molecules, such as peptides, that bind active sites of complement components or enzymes and prevent their participation in the cascade. Their use, however, is hampered by nonspecific side effects or short half-life [214] . Perhaps [227] . Followup studies confirmed this finding in other models of the disease [228] . These experiments suggested that passive immunization with antibodies against human A␤ should decrease the neuritic plaques and this hypothesis was confirmed in transgenic mice, including improved performance in behavioural tests [229, 230] [235] [236] [237] [238] [239] . Antibodies raised by this active immunisation were specific for senile plaques only and did not cross-react with the full-length APP or other derivates [240] . Furthermore, neuropathological evaluation suggested involvement of activated microglia in plaque clearance [239, 241] [235, 243] . Furthermore, despite the apparent success in amyloid clearance, the clinical cognitive benefits from the vaccination were very modest compared to the placebo group [244, 245] [247] . Therefore, the exact mechanism by which this antibody induced these improvements in transgenic animals, remains to be elucidated. 
Anti-amyloid therapy ('vaccination')
The major aim of anti-amyloid therapy is to induce clearance of the amyloid plaques, one of the defining risk factors and pathological hallmarks of AD. A largely unexpected discovery showed that immunization with A␤42 peptide prevents the appearance of amyloid pathology in a transgenic mouse model of AD
Targeting proteasome inhibition
